CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines for serious diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's senior management team will deliver a presentation on Wednesday, February 5, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section. Interested parties can view the fireside chat through the investor relations portal at https://crisprtx.gcs-web.com/events. The recording will remain available for replay on the company's website for 14 days after the presentation.
Positive
- None.
Negative
- None.
ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 2:00 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How long will the CRSP Guggenheim Conference webcast be available for replay?
Where can I watch CRISPR Therapeutics' (CRSP) Guggenheim Conference presentation?
What type of presentation will CRSP deliver at the Guggenheim SMID Cap Biotech Conference?
